About
A named person answers for the method.
Prognyx is not a platform with a research department behind it. It is one person, one published method, and every claim traced to a document you can open.
Who runs Prognyx
Prognyx is Rali Filali, working solo. I founded it because of a gap I kept running into: the biotech with the most riding on a single asset is the one least able to buy competitive intelligence, and the tools built for that gap are all built for someone else's budget.
On credentials, plainly, because this is a field where people check and they should: I am a fifth-year medical student — an M.D. candidate. I am not a physician, not an oncologist, and I do not practise medicine. What the training gives me is the thing that actually matters in oncology competitive intelligence: I can read a trial protocol and know which endpoint was pre-specified, why a hazard ratio of 0.76 with no p-value is not the same claim as a significant result, and what a post-hoc subgroup inside a failed ITT analysis is worth. That is a reading skill, not a title.
The briefs are the credential. Everything Prognyx publishes is in the open, dated, and traced to a primary source you can click. Judge the work.
Why independence is the point
Prognyx has no platform to upsell, no bank behind the read, no sell-side relationship with any company it writes about, and no position in any security it mentions. When a briefing concludes that a company is pressing a Phase 3 on a post-hoc result and a runway that ends in four quarters, nothing in the business model pushes against saying so.
That is not a small thing in this category. Most competitive intelligence a biotech sees is produced by someone with an incentive: a data vendor demonstrating why you need the subscription, a bank marketing a thesis, a consultancy scoping the next project. Prognyx sells the read itself, so the read is the whole product.
What Prognyx does — and doesn't
- Does: continuous watch on the trials, readouts, regulatory actions and deals that touch your assets, mechanisms and indications — and briefs that say what it means and what to do.
- Does: trace every factual claim to a primary record — a ClinicalTrials.gov registration, an SEC filing, an FDA or EMA action, a peer-reviewed publication, a congress abstract.
- Does: say "this cannot be confirmed from public sources" when that is the honest answer, instead of filling the gap.
- Doesn't: give medical advice, clinical guidance, or investment advice. Prognyx analyses public information about competitive positioning. It is not a substitute for regulatory, legal or medical counsel.
- Doesn't: handle your confidential data as a matter of course. A scoping conversation needs your assets and indications — which are usually public — not your unpublished results.
How the work is checked
Every briefing goes through a generator-and-critic separation: the analysis is written, then re-checked claim by claim against its cited source by a separate pass that distrusts by default, plus a freshness gate that re-verifies each cited trial against the live registry and the press record at the moment of publication. Anything that doesn't clear the bar is escalated to me rather than published. The full procedure is written up on how we work.
The reason to publish that procedure rather than just assert quality: in 2026, every competitor in this category runs on machines too, so "we use AI" and "we don't" are both marketing. What can actually be compared is the rule the machines answer to. Prognyx publishes its rule — no fact without a primary source, and a checking pass that is never the pass that wrote — along with the bar a briefing has to clear and what happens to the ones that don't.
Getting in touch
The fastest route is a sample brief: name one asset you'd want watched and you get a real competitive brief on it, free, with no obligation. If you'd rather just ask something, hello@prognyx.com reaches me directly — not a shared inbox, not a form queue.
Prognyx is currently a sole practice, not an incorporated company. Correspondence and data-protection enquiries go to the same address; see the privacy policy for how enquiry data is handled.
Frequently asked
Who writes the Prognyx briefings?
The Prognyx engine writes them: it sweeps the sources, retrieves the primary documents and drafts, and a separate audit pass then re-checks each claim against the source it cites. Rali Filali designed that procedure, sets the audit bar and answers for what Prognyx publishes. The two channels do not share a door: briefings on the blog publish automatically once they clear the bar, while a client brief only goes out when he sends it.
Is Rali Filali a doctor?
No. He is a fifth-year medical student — an M.D. candidate — not a practising physician or oncologist. The relevant skill for competitive intelligence is reading trial protocols, regulatory filings and survival data accurately, which is what the training provides. Prognyx briefings are not medical advice.
Is Prognyx an AI-generated content site?
Yes, and it says so. The briefings are drafted by machine from primary documents, then re-checked claim by claim against those documents by a separate audit pass. What is not generated is the facts: no claim ships without a primary source you can open, and a fact that cannot be confirmed is published as unconfirmed rather than smoothed into a fluent sentence. Blog briefings publish automatically above the audit bar; below it they are held and land on Rali Filali's desk. A client brief never sends itself. The whole procedure is on the methodology page.
Does Prognyx hold a position in the companies it writes about?
No. Prognyx holds no securities in any company it covers, has no sell-side or platform relationship, and receives no compensation from any company it writes about. Its only revenue is client retainers and pilot briefs.
See the next move first.
Tell us the one asset you'd want watched. We'll send back a sample competitive brief on it — sourced, sharp, no strings.
Request a sample brief → How we work